Browse > Article
http://dx.doi.org/10.5483/BMBRep.2013.46.10.268

BAG5 regulates PTEN stability in MCF-7 cell line  

Zhang, Ying (Department of Breast Surgery, QiLu Hospital of Shandong University)
Gao, Haiyan (Central Sterile Supply Department, QiLu Hospital of Shandong University)
Gao, Haidong (Department of Breast Surgery, QiLu Hospital of Shandong University)
Publication Information
BMB Reports / v.46, no.10, 2013 , pp. 490-494 More about this Journal
Abstract
The phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a tumor-suppressing lipid phosphatase that is frequently absent in breast tumors. Thus, the stability of PTEN is essential for tumor prevention and therapy. The ubiquitin-proteasome pathway has an important role in regulating the functions of PTEN. Specifically, carboxyl terminus Hsp70-interacting protein (CHIP), the E3 ubiquitin ligase of PTEN, can regulate PTEN levels. In this study, we report that BCL-2-associated athanogene 5 (BAG5), a known inhibitor of CHIP activity, reduces the degradation of PTEN and maintains its levels via an ubiquitylation-dependent pathway. BAG5 is identified as an antagonist of cell tumorigenicity.
Keywords
BAG5; CHIP; PTEN; Ubiquitin; Ubiquitination;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M. H. and Parsons, R. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947.   DOI   ScienceOn
2 Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D. H. and Tavtigian, S. V. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15, 356-362.   DOI   ScienceOn
3 Carnero, A., Blanco-Aparicio, C., Renner, O., Link, W. and Leal, J. F. (2008) The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr. Cancer Drug Targets 8, 187-198.   DOI   ScienceOn
4 Guldberg, P., thor Straten, P., Birck, A., Ahrenkiel, V., Kirkin, A. F. and Zeuthen, J. (1997) Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57, 3660-3663.
5 Wang, S. I., Parsons, R. and Ittmann, M. (1998) Homozygous deletion of the PTEN tumour suppressor gene in a subset of prostate adenocarcinomas. Clin. Cancer Res. 4, 811-815.
6 Rhei, E., Kang, L., Bogomolniy, F., Federici, M. G., Borgen, P. I. and Boyd, J. (1997) Mutation analysis of the putative tumour suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res. 57, 3657-3659.
7 Di Cristofano, A., Pesce, B., Cordon-Cardo, C. and Pandolfi, P. P. (1998) Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19, 348-355.   DOI   ScienceOn
8 Trotman, L. C., Niki, M., Dotan, Z. A., Koutcher, J. A., Di Cristofano, A., Xiao, A., Khoo, A. S., Roy-Burman, P., Greenberg, N. M., Van Dyke, T., Cordon-Cardo, C. and Pandolfi, P. P. (2003) Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, 385-396.
9 Osaki, M., Oshimura, M. and Ito, H. (2004) PI3K-AKT pathway: its functions and alterations in human cancer. Apoptosis 9, 667-676.   DOI   ScienceOn
10 Maddika, S., Ande, S. R., Panigrahi, S., Paranjothy, T., Weglarczyk, K., Zuse, A., Eshraghi, M., Manda, K. D., Wiechec, E. and Los, M. (2007) Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat. 10, 13-29.   DOI   ScienceOn
11 Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M, Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P. and Mak, T. W. (1998) Negative regulation of PKB/AKT-dependent cell survival by the tumour suppressor PTEN. Cell 95, 29-39.   DOI   ScienceOn
12 Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P. and Yin, Y. (2007) Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128, 157-170.   DOI   ScienceOn
13 Stambolic, V., MacPherson, D., Sas, D., Lin, Y., Snow, B., Jang, Y., Benchimol, S. and Mak, T. W. (2001) Regulation of PTEN transcription by p53. Mol. Cell 8, 317-325.   DOI   ScienceOn
14 Wang, X. and Jiang, X. (2008) Post-translational regulation of PTEN. Oncogene 27, 5454-5463.   DOI   ScienceOn
15 Wang, X., Trotman, L. C., Koppie, T., Alimonti, A., Chen, Z., Gao, Z., Wang, J., Erdjument-Bromage, H., Tempst, P., Cordon-Cardo, C., Pandolfi, P. P. and Jiang, X. (2007) NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128, 129-139.   DOI   ScienceOn
16 Maddika, S., Kavela, S., Rani, N., Palicharla, V. R., Pokorny, J. L., Sarkaria, J. N. and Chen, J. (2011) WWP2 is an E3 ubiquitin ligase for PTEN. Nat. Cell Biol. 13, 728-733.   DOI
17 Ahmed, S. F., Deb, S., Paul, I., Chatterjee, A., Mandal, T., Chatterjee, U. and Ghosh, M. K. (2012) The chaperone-assisted E3 ligase C terminus of Hsc70-interacting protein (CHIP) targets PTEN for proteasomal degradation. J. Biol. Chem. 287, 15996-16006.   DOI
18 Kalia, L. V., Kalia, S. K., Chau, H., Lozano, A. M., Hyman, B.T. and McLean, P. J. (2011) Ubiquitinylation of a-Synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). Plos One. 6, e14695.   DOI   ScienceOn
19 Raftopoulou, M., Manneville, S. E., Self, A., Nicholls, S. and Hall, A. (2004) Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science 303, 1179-1181.   DOI   ScienceOn
20 Sansal, I. and Sellers, W. R. (2004) The biology and clinical relevance of the PTEN tumor suppress or pathway. J. Clin. Oncol. 22, 2954-2963.   DOI   ScienceOn
21 Tamura, M., Gu, J., Matsumoto, K., Aota, S., Parsons, R. and Yamada, K. M. (1998) Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280, 1614-1617.   DOI
22 Liu, J., Xia, H., Kim, M., Xu, L., Li, Y., Zhang, L., Cai, Y., Norberg, H. V., Zhang, T., Furuya, T., Jin, M., Zhu, Z., Wang, H., Yu, J., Li, Y., Hao, Y., Choi, A., Ke, H., Ma, D. and Yuan, J. (2011) Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 147, 223-234.   DOI   ScienceOn
23 Adey, N. B., Huang, L., Ormonde, P.A., Baumgard, M. L., Pero, R., Byreddy, D. V., Tavtigian, S. V. and Bartel, P. L. (2000) Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding. Cancer Res. 60, 35-37.
24 Leslie, N. R. and Downes, C. P. (2004) PTEN function: how normal cells control it and tumour cells lose it. Biochem. J. 382, 1-11.   DOI   ScienceOn
25 Torres, J. and Pulido, R. (2001) The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 276, 993-998.   DOI   ScienceOn
26 Vazquez, F., Ramaswamy, S., Nakamura, N. and Sellers, W. R. (2000) Phosphorylation of the PTEN tail regulates protein stability and function. Mol. Cell Biol. 20, 5010-5018.   DOI
27 Yuan, J., Luo, K., Zhang, L., Cheville, J. C. and Lou, Z. (2010) USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 140, 384-396.   DOI   ScienceOn